Margaret Dawid
About Margaret Dawid
Margaret Dawid serves as the Director of CMC Program Management at Mirati Therapeutics, where she has worked since 2020. With extensive experience in the pharmaceutical industry, she specializes in CAR-T cell therapy and has held various roles in program management and business development across several companies.
Work at Mirati Therapeutics
Margaret Dawid currently serves as the Director of CMC Program Management at Mirati Therapeutics, a position she has held since 2020. In this role, she oversees the development and management of Chemistry, Manufacturing, and Controls (CMC) processes. Her responsibilities include ensuring compliance with regulatory requirements and facilitating the successful progression of drug development projects. Dawid's experience in managing cross-functional teams contributes to her effectiveness in this position.
Previous Experience at Kite Pharma
Prior to her current role, Margaret Dawid worked at Kite Pharma as a Senior Manager in Cell Therapy CMC Program Management from 2019 to 2020. During her tenure, she was involved in the management of CMC activities related to cell therapy products, contributing to the advancement of innovative treatments in the field. Her experience at Kite Pharma added to her expertise in the complexities of cell therapy development.
Education and Expertise
Margaret Dawid holds a Master's degree in Computational Chemistry from Universytet Slaski and a Ph.D. in Organic Chemistry from Silesian University of Technology. Her academic background provides a strong foundation for her expertise in pharmaceutical development, particularly in CAR-T cell therapy, process development, and technology transfer. Dawid's education has equipped her with the skills necessary for managing complex drug development projects.
Background in Pharmaceutical Development
Margaret Dawid has extensive experience in pharmaceutical development, having held various positions in the industry since 2000. She has worked at notable organizations such as Amgen, Norac Pharma, and BioVectra Inc. Throughout her career, she has managed over 30 initiatives supporting drug discovery and development, demonstrating her capability in overseeing projects from preclinical stages to commercial production. Her roles have involved significant contributions to regulatory submissions and compliance.
Achievements in Regulatory Compliance
Throughout her career, Margaret Dawid has developed a solid understanding of regulatory requirements for cGMP API and drug product manufacturing. She has played significant roles in the preparation and review of regulatory documents for global filings, including submissions to regulatory bodies such as the FDA and Health Canada. Her expertise in regulatory compliance has been essential in ensuring that projects meet the necessary standards for successful approval.